
EnPlusOne: Innovating RNA synthesis and solutions for therapeutic applications at commercial scales.
Founded with the mission to revolutionize RNA synthesis, EnPlusOne Biosciences focuses on delivering innovative RNA solutions for therapeutic applications. Their core product, the ezRNA™ synthesis platform, enables the incorporation of diverse nucleotide modifications and promises a sustainable manufacturing process capable of producing therapeutic RNA at commercial scales. EnPlusOne aims to support a wide range of RNA solution applications, positioning itself at the forefront of the emerging RNA therapeutics market.
Notable figures in the company include experts in biotechnology and RNA research, though specific names are not provided. EnPlusOne has garnered attention for its stepwise innovation in RNA synthesis, earning recognition within the biotech community. The impact of their ezRNA™ platform is significant, as it offers a scalable and flexible approach to RNA manufacturing, potentially transforming the landscape of RNA-based therapies and solutions.

ReNAgade Therapeutics
renagadetx.com

Ansa Biotechnologies
ansabio.com

Enzerna
enzerna.com

EzraBio

Inceptive
inceptive.life

rBIO
rbio.online

RNAV8 Bio
rnav8bio.com

Laronde
laronde.bio

Replicate Bioscience

Codexis
codexis.com

Orbital Therapeutics

Alltrna
alltrna.com

Molecular Assemblies

Silvec Biologics
silvec.com

Sensible Biotechnologies
sensible.bio

Alida Biosciences
alidabio.com

Nano RED

Optimeos Life Sciences
optimeos.com

Synlife
synlifebio.com

Vernal Biosciences
vernal.bio
Companies similar to EnPlusOne Biosciences include ReNAgade Therapeutics, Ansa Biotechnologies, Enzerna and EzraBio.
EnPlusOne Biosciences was founded in 2022.
EnPlusOne Biosciences' headquarters is located in Watertown, MA, US.
EnPlusOne Biosciences' most recent funding round was for $12M (USD) in September 2022.
As of Sep 30, 2022, EnPlusOne Biosciences has disclosed funding of $12M (USD).
EnPlusOne Biosciences has 8 employees as of Feb 5, 2024.